Skip to main content
. Author manuscript; available in PMC: 2010 Aug 15.
Published in final edited form as: Cancer Res. 2009 Aug 4;69(16):6546–6555. doi: 10.1158/0008-5472.CAN-09-0605

Figure 6. Imatinib-resistant T315I BCR-ABL transformed cells are sensitive to bortezomib.

Figure 6

a) Representative flow cytometry dot plots (Annexin-V-PE (x-axis) and 7-AAD (y-axis) staining) comparing BaF3/BCR-ABL and BaF3/BCR-ABL T315I cells, treated for 24 hours with 50nM bortezomib, and showing significant induction of apoptosis (cells represented in the LR, UR, and UL quadrants). Imatinib resistance is confirmed in T315I cells. b) Western blot indicating an increase in FoxO3a expression upon bortezomib treatment of BaF3/BCR-ABL T315I cells. c) Bortezomib inhibits both BaF3-BCR-ABL and BaF3-BCR-ABL (T315I) xenograft tumor growth while BaF3/p210 (T315I) tumors do not respond to imatinib inhibition.